GlassScriptPhysician profile
Laura Tessendorf Thompson
NPI 1528823242
$3,858.82
in general payments reported to CMS, 2019-2025
29 companies · $2,289 in 2025
The $2,289 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,570 · 2025: $2,289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,581 · Education: $278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,580.87 |
| Education | $277.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $1,042.72 | 2024-2025 | Mavenclad |
| Abbvie INC. | $620.08 | 2024-2025 | |
| Biogen, INC. | $355.90 | 2024-2025 | Tysabri, Vumerity |
| Teva Pharmaceuticals USA, INC. | $301.21 | 2024-2025 | Austedo Xr, Austedo Xr |
| Lundbeck LLC | $176.57 | 2025 | Vyepti |
| Genentech USA, INC. | $161.48 | 2024-2025 | Ocrevus, Ocrevus Zunovo |
| Pfizer INC. | $151.00 | 2025 | |
| Mallinckrodt Hospital Products INC. | $121.87 | 2025 | Acthar |
| Lilly USA, LLC | $117.30 | 2024-2025 | Kisunla, Amyvid |
| Eisai INC. | $76.85 | 2024-2025 | |
| Argenx US, INC. | $64.69 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Jazz Pharmaceuticals INC. | $64.44 | 2024 | |
| Genzyme Corporation | $63.48 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $51.45 | 2024-2025 | Rexulti |
| Alnylam Pharmaceuticals INC. | $50.83 | 2024-2025 | Amvuttra, Onpattro |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $49.80 | 2025 | Panzyga |
| Ucb, INC. | $45.23 | 2024-2025 | Briviact |
| Neurocrine Biosciences, INC. | $45.21 | 2024 | Ingrezza |
| Scilex Pharmaceuticals INC. | $44.59 | 2024 | |
| Amneal Pharmaceuticals LLC | $41.42 | 2024-2025 | Brekiya, Crexont |
| Mdd US Operations, LLC | $33.98 | 2025 | Gocovri |
| Ani Pharmaceuticals, INC. | $31.63 | 2024 | Purified Cortrophin Gel |
| Vertex Pharmaceuticals Incorporated | $24.88 | 2025 | |
| Medtronic, INC. | $23.72 | 2025 | Inceptiv |
| Tg Therapeutics, INC. | $22.05 | 2025 | |
| Kyowa Kirin, INC. | $20.35 | 2024 | Nourianz |
| Ipsen Biopharmaceuticals, INC | $19.35 | 2024 | Dysport |
| Neurelis, INC. | $19.01 | 2025 | Valtoco |
| Axsome Therapeutics, INC. | $17.73 | 2025 | Symbravo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.